Clinical Trials · NCT05347147
A Trial to Determine the Efficacy and Safety of Presendin in IIH
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Invex Therapeutics Ltd.
- Enrollment
- 14
- Start date
- Nov 2022
- Locations
- 24 sites, 6 countries
- Primary endpoint
- Change in ICP From Baseline to Week 24 Measured by Lumbar Puncture (LP), Where a Higher LP Value Indicates Greater ICP